Search results
Phase 3 Trial Supports Ixekizumab in Juvenile PsA, ERA
Medscape· 5 days agoWith a safety profile comparable with that seen in adult patients, ixekizumab "met the prespecified...
The Swiftly Evolving Story of EGFR-Mutated NSCLC Management
MedPage Today· 3 days ago"Understanding mechanisms of resistance may enable the personalization of sequential...
What Is Long COVID, Exactly? A New Universal Definition May Help More People Access Care
Health.com· 6 days ago“Our committee hopes this single definition, crafted with input from across research and patient...
Slowing inflammation may boost immunotherapy’s e | Newswise
Newswise· 7 days agoPHILADELPHIA – Adding an anti-inflammatory drug to anti-PD1 checkpoint inhibitor immunotherapy has shown great promise as a new strategy against advanced lung cancer, based on results from a ...
Large-Scale Intensive BP Intervention Proves Sustainable for CVD Prevention
MedPage Today· 7 days agoCommunity-based program reduced events regardless of age, diabetes
A New Psychotherapeutic 'Gold Standard' for Chronic Pain?
Medscape· 6 days agoA single course of treatment with emotional awareness and expression therapy (EAET) was associated...
Lawmakers Sharply Question Experts About COVID's Origin
MedPage Today· 7 days agoRon Johnson (R-Wisc.), a member of the Senate Committee on Homeland Security & Governmental Affairs,...
FDA Approves Adagrasib for KRAS G12C–Mutated CRC
Medscape· 4 days agoThis marks the first approval for a KRAS inhibitor to treat CRC.
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market...
Morningstar· 4 days agoFN Media Group News Commentary - The National Cancer Institute’s (NCI) funding of research projects is predicted to empower the Pancreatic Cancer Market to grow. Unlike traditional therapeutic ...
In It Together: Doctor and Patient on GLP-1s
Medscape· 5 days agoEarlier this year, Fernandez found a new clinician who suggested he take a glucagon-like peptide 1 (GLP-1) receptor agonist for weight loss. When...